Soligenix Inc. (NASDAQ: SNGX) announced that President and CEO Christopher J. Schaber, Ph.D., will deliver a corporate presentation at the BIO Investment & Growth Summit on March 2 at 3 p.m. The conference, scheduled for March 2-3 at Eden Roc Miami Beach in Florida, focuses on growth-stage biotechnology companies through presentations, one-on-one meetings, and specialized programming. Additional information is available on the conference website.
This presentation is significant as it provides investors and industry stakeholders with a crucial update on Soligenix's late-stage development pipeline. The company is a biopharmaceutical firm focused on rare diseases with unmet medical needs, making its progress particularly important for patient populations with limited treatment options. The timing coincides with key regulatory milestones, potentially influencing investment decisions and partnership opportunities in the competitive biotech sector.
Soligenix's Specialized BioTherapeutics segment is advancing HyBryte™ (SGX301), a novel photodynamic therapy using visible light for cutaneous T-cell lymphoma (CTCL). With successful completion of a second Phase 3 study, the company is preparing for global regulatory submissions, which could lead to commercialization. This development addresses a critical gap in CTCL treatment, offering a safer alternative to existing therapies. The segment also includes SGX302 for psoriasis, dusquetide (SGX942) for inflammatory diseases like oral mucositis in head and neck cancer, and SGX945 for Behçet's Disease, expanding its impact across multiple rare conditions.
The Public Health Solutions segment features vaccine candidates supported by government funding, including RiVax® for ricin toxin, filovirus vaccines for Marburg and Ebola, and CiVax™ for COVID-19. These programs utilize the proprietary ThermoVax® heat stabilization platform, enhancing vaccine stability and distribution potential. Funding from agencies like the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA) underscores the strategic importance of these initiatives for public health preparedness.
For investors, the latest updates on Soligenix are available in the company's newsroom, providing transparency and ongoing engagement. The BIO Investment & Growth Summit serves as a platform to highlight these advancements, emphasizing Soligenix's role in addressing rare diseases and public health threats. The implications extend beyond financial markets, potentially accelerating treatment access for underserved patients and contributing to global health security through innovative vaccine technologies.
